A Prospective, Randomized Study to Compare the Effect of Campath-1, Low Dose Sirolimus Versus Campath-1H, Low Dose CsA Both in Addition to Low Dose Mycophenolate Mofetil on Phenotypic and Functional Profiles of PBMCs in Kidney Transplant Recipients in a Steroid-Free Regimen

Trial Profile

A Prospective, Randomized Study to Compare the Effect of Campath-1, Low Dose Sirolimus Versus Campath-1H, Low Dose CsA Both in Addition to Low Dose Mycophenolate Mofetil on Phenotypic and Functional Profiles of PBMCs in Kidney Transplant Recipients in a Steroid-Free Regimen

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Oct 2009

At a glance

  • Drugs Alemtuzumab (Primary) ; Ciclosporin; Methylprednisolone; Mycophenolate mofetil; Sirolimus
  • Indications Renal transplant rejection
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 06 Apr 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top